Compare MakeMyTrip Ltd (MMYT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Neurocrine Biosciences Inc — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.5× MakeMyTrip Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MMYT | NBIX | |
|---|---|---|
Market Cap | $4.09B | $14.36B |
Volume | 1,828,010 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.25 | $185.50 |
52-Week Low | $36.30 | $123.10 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | $4.75B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $43.53, up 0.28% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported mixed quarterly earnings, with a Q1 2026 beat and Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, but net income margin compressed to 3.23% in 2026. Analyst consensus is strongly bullish with a $77.00 price target, though institutional selling has been noted recently.
The outlook is bifurcated: strong analyst support and a potential Indian listing offer upside, but declining profitability, high P/E ratio, and bearish technicals pose risks. Investors face volatility from operational execution and travel industry cyclicality against a backdrop of Wall Street optimism.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
